Zepbound: Weight Loss Dosing and Tracking

Quick Reference

• What it is: Tirzepatide, a dual GIP/GLP-1 receptor agonist
• What it treats: Chronic weight management in adults with obesity or overweight with comorbidities (FDA-approved)
• How it's administered: Once-weekly subcutaneous injection via single-dose pre-filled pen
• Standard dosing range: 2.5 mg (initiation) to 15 mg (maximum maintenance)
• Needle: 31-gauge, 4 mm (hidden in pen)

Zepbound is tirzepatide for chronic weight management. FDA-approved in November 2023, it's the same molecule as Mounjaro but labeled for obesity and overweight -- and it delivered the largest average weight loss numbers ever seen in a pharmaceutical trial at the time of its approval. If you're on Zepbound or considering it, this page covers the mechanism, dosing, injection technique, side effects, monitoring, and how to track your treatment.

What Zepbound Is

Zepbound is Eli Lilly's brand name for tirzepatide when prescribed for weight management. It's identical to Mounjaro at the molecular level -- same active ingredient, same pen device, same dose strengths (2.5 mg through 15 mg). The difference is the FDA indication and the prescribing context.

Like Mounjaro, Zepbound comes as single-dose pre-filled pens, color-coded by dose:

Four pens per monthly box. New dose strength each time you escalate.

Zepbound is a long-term medication. The SURMOUNT trials measured outcomes over 72 weeks, and the weight regain data mirrors what we've seen with semaglutide: stopping treatment leads to significant weight regain. This is consistent with how incretin-based therapies work -- they modify appetite and metabolic signaling, and those effects reverse when the drug is withdrawn.

How It Works

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates two incretin hormone pathways simultaneously, which is mechanistically distinct from GLP-1-only drugs like semaglutide.

For weight management, the relevant effects are:

• Appetite suppression: GLP-1 receptor signaling in the hypothalamus reduces hunger. GIP receptor co-activation appears to amplify this effect. Patients consistently describe a meaningful reduction in food preoccupation -- the persistent background urge to eat diminishes significantly.
• Delayed gastric emptying: Food moves through the stomach more slowly, extending the feeling of fullness after meals and reducing meal size naturally.
• Improved energy metabolism: GIP receptor activation influences how the body handles fat storage and mobilization. Preclinical data suggests it improves the metabolic efficiency of adipose tissue, which may contribute to the magnitude of weight loss beyond what GLP-1 alone achieves.
• Insulin sensitivity: Even without a diabetes diagnosis, many people with obesity have some degree of insulin resistance. Tirzepatide improves insulin sensitivity, which has downstream metabolic benefits.

The dual mechanism is the leading explanation for why tirzepatide produces greater weight loss than semaglutide in comparable populations. SURMOUNT-1 participants on tirzepatide 15 mg lost an average of 22.5% of body weight -- roughly 7-8 percentage points more than what STEP 1 showed for semaglutide 2.4 mg, though these were different trials with different populations and direct comparison has limitations.

For the full tirzepatide mechanism and trial data, see our tirzepatide guide.

Approved Uses

Zepbound is FDA-approved for:

Chronic weight management in adults with:

• A BMI of 30 or greater (obesity), or
• A BMI of 27 or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease)

It is intended as an adjunct to reduced-calorie diet and increased physical activity.

Zepbound is not approved for type 2 diabetes management. That indication belongs to Mounjaro. They are the same molecule with different labels -- a regulatory distinction, not a pharmacological one.

Cardiovascular outcome data for tirzepatide in an obesity population is pending from the SURMOUNT-MMO trial. As of this writing, Zepbound does not carry a cardiovascular risk reduction indication. Wegovy (semaglutide) is the only weight management GLP-1 medication with proven cardiovascular outcome data (from the SELECT trial).

Dosing

Zepbound follows the same titration ladder as Mounjaro, escalating in 2.5 mg increments:

The minimum effective dose for weight management is 5 mg. Your prescriber will decide how high to titrate based on your weight loss response, tolerability, and treatment goals.

In SURMOUNT-1, participants were randomized to fixed-dose arms of 5, 10, or 15 mg. All three produced clinically significant weight loss:

• 5 mg: 15.0% average weight loss at 72 weeks
• 10 mg: 19.5%
• 15 mg: 22.5%

This means meaningful results don't require the maximum dose. Some patients find 10 mg provides sufficient weight loss with fewer side effects than 15 mg. That's a legitimate clinical decision, not a failure to titrate.

Dose timing: Same day each week, any time, with or without food. Minimum 3 days (72 hours) between doses if changing your injection day.

Missed dose: Take it within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip it and inject on your next scheduled day.

Injection Sites and Technique

The Zepbound pen is identical to the Mounjaro pen -- single-dose, pre-filled, hidden 31-gauge 4 mm needle.

Approved sites

• Abdomen: At least 2 inches from the navel. Avoid waistband areas.
• Front of the thigh: Anterior mid-thigh.
• Back of the upper arm: Easier with help.

Technique

1. Remove pen from refrigerator 30 minutes before use.
2. Check the solution through the inspection window -- it should be clear, colorless to slightly yellow, and particle-free.
3. Pull off the gray base cap.
4. Place the clear base flat against your skin. Do not pinch.
5. Unlock by turning the lock ring.
6. Press and hold the purple injection button. First click = injection starts. Second click = injection complete.
7. Hold for 10 seconds after the second click.
8. Remove and discard in a sharps container.

No priming, no dose dialing. If you release the button before the second click or the pen malfunctions, do not re-inject. Contact your prescriber or pharmacist.

Site rotation

Rotate weekly. The same rotation systems that work for Mounjaro work for Zepbound -- they're the same pen and the same injection. Divide your abdomen into quadrants, alternate with thigh sites, and cycle through on a repeating schedule.

Our GLP-1 injection site rotation guide provides detailed rotation systems with tracking templates.

Side Effects to Track

The side effect profile comes primarily from the SURMOUNT trial series, which studied tirzepatide in a non-diabetic obesity population.

Common (from SURMOUNT-1, 15 mg arm)

• Nausea: 33% (vs. 9% placebo). The most frequent complaint. Most common in the first 1-2 weeks after each dose increase.
• Diarrhea: 25% (vs. 10% placebo).
• Constipation: 17% (vs. 4% placebo).
• Vomiting: 13% (vs. 2% placebo).
• Dyspepsia/heartburn: 10%.
• Abdominal pain: 7%.
• Injection site reactions: 7%.

The GI side effect rates in SURMOUNT-1 are higher than in the SURPASS diabetes trials, likely because the weight management population was titrated more aggressively in some cases and because GI effects may present differently in people without diabetes.

Treatment discontinuation due to adverse events was 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) compared to 2.6% for placebo. Most discontinuations were GI-related.

Less common but clinically significant

• Gallbladder events: Gallstones reported at higher rates with rapid weight loss. SURMOUNT-1 showed cholelithiasis in ~1.5% of tirzepatide participants vs. 0.6% placebo.
• Pancreatitis: Rare but serious. Severe abdominal pain radiating to the back warrants immediate medical attention.
• Hair loss: Reported by some participants, likely related to rapid weight loss and caloric deficit rather than the drug itself. Temporary in most cases.
• Hypoglycemia: Uncommon in non-diabetic patients. More relevant if you have undiagnosed prediabetes or are taking other glucose-lowering medications.
• Mood changes: The FDA has required monitoring for suicidal ideation and behavioral changes with all GLP-1 agonists.

Boxed warning

Same as all tirzepatide and GLP-1 products: thyroid C-cell tumors in rodent studies. Not confirmed in humans. Contraindicated with personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.

What to Monitor

Clinical measures

• Weight: Weekly, same conditions (morning, post-void, pre-meal). This is the primary outcome measure. Track trends, not day-to-day fluctuations.
• Waist circumference: Monthly. A better proxy for visceral fat loss and metabolic improvement than scale weight alone.
• Body composition: If accessible (DEXA scan, bioimpedance), periodic body composition measurement helps distinguish fat loss from lean mass loss. Resistance training during treatment preserves muscle mass.
• Blood pressure: Monthly. Weight loss often lowers BP, which may require antihypertensive dose adjustment.

Bloodwork

• Lipid panel: Baseline and every 3-6 months. Triglycerides and LDL typically improve with significant weight loss.
• HbA1c / fasting glucose: Even without diabetes, tracking metabolic markers helps quantify the metabolic benefit. Many patients with prediabetes see normalization.
• Liver enzymes (ALT, AST): Baseline and periodically. Metabolic-associated fatty liver disease often improves.
• Kidney function (eGFR): Baseline and periodic, particularly if GI side effects cause significant fluid loss.
• Thyroid function: Baseline recommended. Not because tirzepatide affects the thyroid in humans (no evidence of this), but because thyroid disorders can independently affect weight.

Self-tracking

• Appetite: Rate hunger daily on a 1-10 scale. This subjective measure is surprisingly useful -- it flags when the drug is working, when a dose increase is taking effect, and whether appetite unexpectedly returns (which could signal an absorption issue or missed dose).
• GI symptoms: Severity, timing relative to injection, duration. Your prescriber needs this to make titration decisions.
• Energy and mood: Caloric deficit and rapid weight loss affect both. Track patterns so you can distinguish drug effects from lifestyle factors.
• Physical activity: Document type, duration, and frequency. The combination of tirzepatide and exercise produces better body composition outcomes than either alone.

Comparison to Alternatives

Zepbound's distinguishing advantage is the magnitude of weight loss -- the highest of any approved pharmaceutical. The trade-off is the absence of cardiovascular outcome data (pending) and a shorter real-world track record compared to Wegovy, which has SELECT trial data and more years of post-market use. Saxenda requires daily injections. Contrave is oral but produces substantially less weight loss.

A head-to-head trial of tirzepatide vs. semaglutide for weight management (SURMOUNT-5) has been completed. Tirzepatide demonstrated statistically superior weight loss: 20.2% vs. 13.7% for semaglutide at 72 weeks. This was the first direct comparison of these two drugs in an obesity population.

Tracking Your Treatment

Zepbound's multi-step titration over months demands structured tracking. You're changing doses regularly, your body is adjusting at each level, and the interplay between weight loss, appetite changes, and side effects creates a dynamic picture that's impossible to hold in memory.

What to log each week:

• Date and time of injection
• Dose level (critical -- you may be on any of six dose strengths)
• Pen color (quick visual confirmation you're injecting the right dose)
• Injection site and side
• Side effects within 72 hours, with severity and duration
• Weight
• Appetite rating (1-10)
• Next scheduled injection date

Over the course of treatment, this log tells a story: how your body responded at each dose, when side effects peaked and resolved, what rate of weight loss you sustained, and whether specific patterns (exercise, hydration, sleep) correlated with better or worse weeks. That's data your prescriber can use to optimize your treatment.

Done Dose is built for this. Track your Zepbound titration from 2.5 mg to your maintenance dose, log injections and site rotation in seconds, record side effects and weight, and have your complete treatment history ready when your prescriber needs it.

Frequently Asked Questions

How much weight can you lose on Zepbound?

In the SURMOUNT-1 trial, participants on the highest tirzepatide dose (15 mg) lost an average of 22.5% of their body weight over 72 weeks, compared to 2.4% with placebo. At the 10 mg dose, average loss was 19.5%. Individual results depend on dose, adherence, diet, and exercise.

Is Zepbound the same as Mounjaro?

Both contain tirzepatide, the same molecule made by Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. They use identical pen devices and dose strengths, but have different FDA labels and may have different insurance coverage.

How often do you inject Zepbound?

Once weekly, on the same day each week, at any time of day. If you need to change your injection day, at least 3 days (72 hours) must have passed since your last dose.

What are the most common Zepbound side effects?

Gastrointestinal side effects are the most frequently reported: nausea (24-33%), diarrhea (18-25%), vomiting (6-13%), and constipation (11-17%). These are most common during dose escalation and typically diminish at each stable dose level.

How long does it take to reach the full Zepbound dose?

The standard titration takes at least 16 weeks: 4 weeks at 2.5 mg, then escalation in 2.5 mg increments every 4 weeks. Reaching 15 mg takes 24 weeks minimum if you escalate at every step. Not everyone needs the maximum dose -- many people achieve meaningful results at 10 or 12.5 mg.

Sources

1. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." The New England Journal of Medicine, 2022. DOI: 10.1056/NEJMoa2206038
2. Garvey WT, et al. "Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)." JAMA, 2023. DOI: 10.1001/jama.2023.24945
3. U.S. Food and Drug Administration. "FDA Approves New Medication for Chronic Weight Management." fda.gov
4. Eli Lilly and Company. "Zepbound (tirzepatide) Prescribing Information." uspl.lilly.com/zepbound
5. Frias JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)." The New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2107519

Done Dose tracks your Zepbound titration, injection sites, side effects, and weight loss progress -- everything in one place. Download Done Dose to stay consistent with your weekly injections.